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ABSTRACT: A novel cell-targeting, pH-sensitive poly-
meric carrier was employed in this study for delivery of
the anticancer drug bortezomib (BTZ) to cancer cells. Our
strategy is based on facile conjugation of BTZ to catechol-
containing polymeric carriers that are designed to be taken
up selectively by cancer cells through cell surface receptor-
mediated mechanisms. The polymer used as a building
block in this study was poly(ethylene glycol), which was
chosen for its ability to reduce nonspeciﬁc interactions with
proteins and cells. The catechol moiety was exploited for its
ability to bind and release borate-containing therapeutics
such as BTZ in a pH-dependent manner. In acidic environ-
ments, such as in cancer tissue or the subcellular endosome,
BTZ dissociates from the polymer-bound catechol groups
toliberatethefreedrug,whichinhibitsproteasomefunction.
A cancer-cell-targeting ligand, biotin, was presented on the
polymer carriers to facilitate targeted entry of drug-loaded
polymer carriers into cancer cells. Our study demonstrated
that the cancer-targeting drug polymer conjugates drama-
tically enhanced cellular uptake, proteasome inhibition, and
cytotoxicitytowardbreastcarcinomacellsincomparisonwith
nontargeting drug polymer conjugates. The pH-sensitive
catechol boronate binding mechanism provides a chemo-
selective approach for controlling the release of BTZ in
targeted cancer cells, establishing a concept that may be
applied in the future toward other boronic acid-containing
therapeutics to treat a broad range of diseases.
T
argeted drug delivery systems aim to improve the eﬃcacy
and reduce the toxicity of potent therapeutics in treatments
foravariety ofdiseases. For example, chemotherapyisoneofthe
major systemic treatments for cancer, but it is linked to serious
side eﬀects because of its toxicity to normal proliferating cells.
Cancer-targeting delivery systems have been developed to alter
thebiodistributionofdrugs,aimingtoachievedrugaccumulation
in cancer tissue through the enhanced permeability and reten-
tion (EPR) eﬀect and/or targeting of the cancer cell surface.
1
Advanceddeliverysystemsforanticancerdrugsoftenutilizeenvi-
ronmentally triggered mechanisms.
2 4 For example, the extra-
cellular pH in tumor tissue is slightly lower than that in normal
tissue, and this has been exploited to accomplish pH-triggered
drug release in tumor tissue.
5 In addition, the signiﬁcantly
increased acidity in subcellular compartments such as the
endosome also oﬀers a complementary route to increases in
the eﬃcacy of anticancer drug deliveryvia pH-initiated release of
drugs from endocytosed drug carriers.
5,6
Here we describe a novel polymer conjugate of the anticancer
drug bortezomib (BTZ) that can be used for pH-sensitive
delivery to speciﬁc cancer cells. BTZ is a dipeptide boronic acid
analogue that inhibits cancer cell proteasome through direct
bindingbetweenitsboronicacidgroupandthreonineresiduesin
the active sites of several proteases.
7,8 This drug is currently
marketed as Velcade (Millenium Pharmaceuticals) and has been
approved for multiple myeloma and mantle cell lymphoma
treatment;however,BTZislessactiveagainstmanysolidtumors
and has signiﬁcant dose-limiting toxicity.
9,10 In addition to the
possibility that diﬀerent cancer cells may have distinct protea-
some sensitivity to BTZ,
11,12 the unfavorable pharmacokinetic
properties ofBTZ,including nonspeciﬁcbindingtoproteins and
rapid hepatic clearance from blood, may also contribute to its
limited eﬃcacy against solid tumors.
13,14 This suggests that
polymeric delivery vehicles capable of enhancing the pharmaco-
kinetic properties of BTZ may improve its activity against solid
tumors. Moreover, strategies to direct BTZ to cancer cells by
speciﬁc cell surface recognition epitopes and/or trigger pH-
regulated drug release may facilitate drug delivery and release
in tumors, thereby potentially increasing the eﬃcacy and redu-
cing the toxicity of BTZ.
It has been previously reported that polyphenols can chemi-
cally block the proteasome-inhibiting activity of BTZ through
conjugation to the boronic acid active site and that the formed
conjugatescannotpermeatefreelythroughthecellmembrane.
15 18
Our design takes advantage of the facile conjugation of BTZ to
the 1,2-benzenediol (catechol) moiety to form a membrane-
impermeable compound in order to reduce nonselective cellular
uptake of the drug. An important characteristic of the boronic
acid catechol conjugate is that it is formed through dynamic
covalent chemistry that is reversible in a pH-sensitive manner:
19
at neutral or alkaline pH, BTZ and catechol form a stable
boronate ester, which deactivates the cytotoxicity of BTZ; in a
low-pH environment, the BTZ catechol ester conjugate readily
dissociates to release free BTZ and catechol groups. This
mechanism has the potential to be exploited in two contexts:
(1) extracellularly for localized drug release within the mildly
acidic tumor interstitium and (2) intracellularly in the more
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acidic endosomes following cell surface receptor-mediated en-
docytosis. In both cases, the acidic environment would result in
dissociation of BTZ from the polymer-bound catechol groups,
activating its proteasome-inhibiting function (Figure 1).
We ﬁrst characterized the pH-dependent reversible binding
between BTZ and catechol compounds using
1H NMR spec-
troscopy(Figure2A).AtpH5.5,amixtureofBTZanddopamine
(DA) produced a spectrum similar to that of the two individual
compounds superimposed upon each other, indicating the pre-
sence ofuncomplexed BTZ and DA.However, the same mixture
atpH7.4gaveaspectrumwithstrikingchangesinchemicalshifts
and peak splittings, revealing the formation of a BTZ DA
conjugate. To investigate further the pH sensitivity of BTZ 
catechol dissociation, preformed BTZ DA conjugate [0.1 M in
deuterateddimethylsulfoxide(DMSO-d6)]wasdilutedto1mM
in deuterated phosphate buﬀer at pH 5.5 8.5 and then analyzed
by NMR spectroscopy (Figure SI 1 in the Supporting In-
formation). The peak integrals in the ranges 7.0 7.2, 6.6 6.8,
and 5.5 6.5 ppm, corresponding to the H atoms on the phenyl
ring of BTZ, the benzene ring of free DA, and the benzene of the
BTZ DA complex, respectively, were used to estimate the
degreeofBTZ DAcomplexation.AsshowninFigure2B,disso-
ciation of the BTZ DA complex increased as the pH decreased
from 8.5 to 6.5, and the BTZ DA complex was undetectable at
pH 5.5.
ThepHdependenceoftheBTZ catecholcomplexsuggested
that polymer constructs containing catechols may be useful for
pH-triggered release of BTZ. We therefore synthesized several
BTZ polymer constructs as pH-responsive carriers of BTZ to
cancer cells (Scheme 1). We employed a modular heterobifunc-
tional polymer design consisting of a poly(ethylene glycol)
(PEG) polymer derivatized with one or more catechols and a
cell-targeting moiety. PEG is well-known to reduce nonspeciﬁc
interactions of therapeutic molecules with proteins and cells and
therefore has been widely applied in the form of drug PEG
conjugates that exhibit reduced drug degradation and extended
drug circulation time.
20 Here we used biotin as a cell-targeting
ligand because previous reports have shown that biotinylated
polymers can be selectively taken up by cancer cells.
21,22 Although
thebiotinreceptors/transportersoncancercellsurfaceshavenot
been well-characterized, biotin has a relatively simple structure
and thus can also be used as a tag for cellular tracking of polymer
drug carriers, making this molecule an attractive choice for
demonstrating cancer cell targeting. We used ﬂuorescence
microscopy to examine the uptake of ﬂuorescein isothiocyanate
(FITC)-labeled biotinylated PEG (biotin PEG FITC) into
two breast cancer cell lines, MDA-MB-231 cells and MCF-10A-
H-RasV12 cells, as well as the nontransformed or noncancerous
breastepithelialcelllineMCF-10A-Vector.
23Figure3showsthat
biotin PEG FITC was rapidly taken up by cells, whereas the
cellular uptake of PEG FITC without the biotin moiety was
minimal. The uptake of biotinlylated polymers was inhibited
by free biotin in a dose-dependent manner (Figure SI 3),
demonstratingthatpolymeruptakebycellsismediatedbythe
cell surface receptor for biotin. Notably, the inhibition of
uptakeofbiotinylatedpolymerbyfreebiotinwaslessrobustin
cancer cell lines (MDA-MB-231 and MCF-10A-H-RasV12)
than in noncancer MCF-10A-Vector cells, suggesting greater
expression levels of biotin receptors in cancer cells than in
noncancer cells.
After conﬁrming the cancer-targeting function of the biotin
ligand, we synthesized PEG polymers containing four catechol
Figure 1. pH-sensitive polymer drug conjugates for delivering BTZ
selectively into cancer cells. (A) The catechol and the boronic acid
structure in BTZ form a stable, covalently-bonded, inactive conjugate at
neutral and alkaline pH, but this structure dissociates in acidic environ-
ments to release the free active drug. (B) The catechol polymer BTZ
conjugate may dissociate in response to a mildly acidic cancer tissue
microenvironment to liberate the free drug, which can be taken up by
cancer cells. Alternatively, through the use of a targeting ligand, the
catechol polymer BTZ conjugate may be transported intact into the
cell via receptor-mediated endocytosis, whereupon the acidic environ-
ment of the endosome induces intracellular drug release.
Figure 2. pH-dependent interactions between BTZ and DA. (A)
1H
NMR spectra of BTZ and DA in deuterated PBS at pH 5.5 and 7.4. DA
was chosen as a representative catechol-containing model compound
whose conjugate with BTZ is fully soluble in aqueous solutions. Circled
in red are proton signals resulting from the formation of a stable
BTZ DA conjugate at pH 7.4, which are not present at pH 5.5. (B)
Peak integrals in the pH ranges 7.0 7.2, 6.6 6.8, and 5.5 
6.5 ppm were used to estimate the degree of BTZ DA binding at
pH 5.5 8.5.
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groupseach(BPCandPC;Scheme1)inordertotakeadvantage
of multiple catechol moieties to increase the drug-loading
capacity of the polymeric carrier. Time-dependent release of
BTZ from these catechol polymers was carried out in buﬀered
solutions at pH 7.4, 6.5, and 5.0, mimicking the physiological pH
in normal tissue and blood, the tumor extracellular environment,
and subcellular endosome, respectively. Figure 4 shows that at
pH 7.4, ∼30% of the BTZ was released from both BPC and PC
over a 12 h period, while >80% of the BTZ was released from
these catechol polymers at pH 5.0. This further conﬁrmed the
pH-dependent BTZ dissociation from the catechol-presenting
polymericdeliveryvehicles,whichcouldrenderBTZnon-cell-
permeable and inactive in normal tissues but allow the BTZ
activity to be recovered in cancer tissue, where the acidity
increases.
The eﬀects of polymer BTZ conjugates on proteasome inhi-
bition and cell viability were ﬁrst evaluated using MDA-MB-231
breast cancer cells (Figure 5 A,B). The untargeted (no biotin
ligand) PC BTZ conjugate exhibited dramatically decreased
proteasome inhibition in comparison to free BTZ, indicating
deactivation of BTZ due to formation of the BTZ catechol
polymer conjugate. This result is consistent with the previously
reported inhibition of BTZ activity by polyphenols,
15,16,18 which
we speculate may be due to the inability of BTZ catechol
complexes to enter cells. In stark contrast, the biotinylated
conjugate BPC BTZ retained high proteasome-inhibiting ac-
tivity. Cell viability assays 48 h after treatment of cells with the
polymer BTZ conjugates demonstrated a similar pattern: the
biotin-receptor-targeting BPC BTZ conjugate maintained
fairly high cytotoxicity of BTZ, whereas catechol-containing
polymers (BPC and PC) without loaded drug exhibited little
proteasome inhibition activity or cytotoxicity. These results
suggest that cellular uptake of the polymer BTZ conjugate
through biotin-receptor-mediated transport can restore the
BTZ activity within the cells, possibly via internalization of the
polymer BTZ conjugate followed by low-pH-triggered intra-
cellulardissociation of BTZ fromthe polymer inthe endosomes.
Adetailedinvestigationoftheintracellular eventsresponsiblefor
this eﬀect is in progress. Some preliminary evidence for self-
assembly of the polymer BTZ construct into nanostructures
was observed by cryogenic transmission election microscopy
(cryo-TEM) (Figure SI 2). However, the signiﬁcance of these
structures in relation to the observed cytotoxic eﬀects requires
further study.
To evaluate further the selectivity of the polymer drug
conjugates for cancer cells over normal cells, we treated immor-
talized human mammary epithelial cells (MCF-10A-Vector cells,
a noncancer control) and transformed MCF-10A-H-RasV12
cells with BPC BTZ (0, 10, and 25 nM). We found that BPC
loaded with BTZ at 25 nM concentration induced 1.7-fold
increased cell death in the cancer cell line relative to the control
cells (Figure SI 5). Calculated IC50 values for cell growth
inhibition by BPC BTZ and free BTZ revealed that cancer
cells were 2.2-fold more sensitive to BPC BTZ than noncancer
Figure 4. Time-dependent release of BTZ from the catechol polymers
BPC and PC at pH 5.0, 6.5, and 7.4. The fraction of BTZ released
was 30% from both polymers at pH 7.4 over 12 h, while >80% of
the BTZ was released at pH 5.0 in the same period of time. Drug 
polymer conjugates formed between 0.2 mM BTZ and 0.05 mM BPC
orPCwereusedforallmeasurementsofreleasein10mMPBSbuﬀersat
37  C.
Figure 5. Cytotoxicity of catechol polymer BTZ conjugates toward
breast cancer cells. (A) Proteasome inhibition assays 6 h after treatment
of MDA-MB-231 cells with (I) free BTZ, (II) BPC BTZ, (III)
PC BTZ, (IV) BPC without BTZ, and (V) PC without BTZ. (B) Cell
deathasdeterminedbyﬂuorescenceimaging48haftertreatmentusinga
commercialcellviabilityassaykit(calceinAMforlivecellsandethidium
homodimer-1 for dead cells). (C) IC50 values of BPC BTZ estimated
from MTS assays indicate the enhanced cytotoxicity of BPC BTZ
toward cancer cells relative to noncancer cells.
Figure 3. Selective uptake of ﬂuorescent FITC-terminated PEG mol-
ecules by cancer cells (MDA-MB-231 and MCF-10A-H-RasV12) and
noncancerous cells (MCF-10A-Vector). All cells showed robust uptake
of biotin PEG FITC but little uptake of PEG FITC. Free biotin
(0.1 μM) in the culture medium inhibited uptake of biotin PEG 
FITCbynoncancerouscellsand,toalesserextent,bythetwocancercell
lines, indicating that the cellular entry of FITC-terminated polymers is
mediated by biotin receptors on the cell surface and that the expression
of these receptors on cancer cell surfaces is very likely higher than on
noncancerous cell surfaces.11853 dx.doi.org/10.1021/ja203077x |J. Am. Chem. Soc. 2011, 133, 11850–11853
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cells, while both cell types were equally sensitive to free BTZ
(Figure 5C). This result suggests that cancer cells are more
susceptible to BPC BTZ toxicity than noncancer cells, a major
potentialtherapeutic advantage of our targeted polymeric carrier
platform.
Thisworkhasdemonstratedtargeteddeliveryofananticancer
drug to cancer cells using catechol-presenting polymers. These
polymericdrugcarriershaveachemicallydeﬁnedmechanism for
drug loading and release through the pH-sensitive cate-
chol boronic acid interaction. With the use of biotin to target
cancer cells, the proteasome inhibitor bortezomib delivered by
such polymeric carriers showed enhanced cytotoxicity against
breastcancercellscomparedtononcancercellsinvitro.Variation
of the catechol polymer architecture and composition and the
choice of boronic acid-containing therapeutic can potentially
provide great tailorability of catechol polymer boronic acid com-
plexes for a variety of drug delivery applications. For instance,
alternative targeting ligands can be exploited to alter the tissue
biodistribution, and modiﬁcations of the chemical structure of
thecatechol (or,moregenerally,diolgroups)canbeexploitedto
ﬁne-tunethepHsensitivityofthediol boronicacidcomplexfor
drug release in diﬀerent tissue environments.
24,25 Since the
boronic acid structure exisits in many potent therapeutics,
26 28
thispH-sensitivestrategymayprovideaversatile,chemoselective
approach for targeted drug delivery to diseased tissues resulting
from a broad spectrum of disorders.
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